Cell Death and Disease (Mar 2023)

Mutations in the B30.2 and the central helical scaffold domains of pyrin differentially affect inflammasome activation

  • Daria Chirita,
  • Pauline Bronnec,
  • Flora Magnotti,
  • Sarah Dalmon,
  • Amandine Martin,
  • Michel Popoff,
  • Mathieu Gerfaud-Valentin,
  • Pascal Sève,
  • Alexandre Belot,
  • Anne Contis,
  • Agnes Duquesne,
  • Gaetane Nocturne,
  • Irene Lemelle,
  • Sophie Georgin-Lavialle,
  • Guilaine Boursier,
  • Isabelle Touitou,
  • Yvan Jamilloux,
  • Thomas Henry

DOI
https://doi.org/10.1038/s41419-023-05745-9
Journal volume & issue
Vol. 14, no. 3
pp. 1 – 13

Abstract

Read online

Abstract Familial Mediterranean Fever (FMF) is the most common monogenic autoinflammatory disorder. FMF is caused by mutations in the MEFV gene, encoding pyrin, an inflammasome sensor. The best characterized pathogenic mutations associated with FMF cluster in exon 10. Yet, mutations have been described along the whole MEFV coding sequence. Exon 10 encodes the B30.2 domain of the pyrin protein, but the function of this human-specific domain remains unclear. Pyrin is an inflammasome sensor detecting RhoA GTPase inhibition following exposure to bacterial toxins such as TcdA. Here, we demonstrate that the B30.2 domain is dispensable for pyrin inflammasome activation in response to this toxin. Deletion of the B30.2 domain mimics the most typical FMF-associated mutation and confers spontaneous inflammasome activation in response to pyrin dephosphorylation. Our results indicate that the B30.2 domain is a negative regulator of the pyrin inflammasome that acts independently from and downstream of pyrin dephosphorylation. In addition, we identify the central helical scaffold (CHS) domain of pyrin, which lies immediately upstream of the B30.2 domain as a second regulatory domain. Mutations affecting the CHS domain mimic pathogenic mutations in the B30.2 domain and render the pyrin inflammasome activation under the sole control of the dephosphorylation. In addition, specific mutations in the CHS domain strongly increase the cell susceptibility to steroid catabolites, recently described to activate pyrin, in both a cell line model and in monocytes from genotype-selected FMF patients. Taken together, our work reveals the existence of two distinct regulatory regions at the C-terminus of the pyrin protein, that act in a distinct manner to regulate positively or negatively inflammasome activation. Furthermore, our results indicate that different mutations in pyrin regulatory domains have different functional impacts on the pyrin inflammasome which could contribute to the diversity of pyrin-associated autoinflammatory diseases.